Results 41 to 50 of about 83,725,006 (209)

BDNF downregulates 5-HT2A receptor protein levels in hippocampal cultures

open access: yes, 2009
Both brain-derived neurotrophic factor (BDNF) and the serotonin receptor 2A (5-HT2A) have been related to depression pathology. Specific 5-HT2A receptor changes seen in BDNF conditional mutant mice suggest that BDNF regulates the 5-HT2A receptor level ...
Santini, M.A.   +28 more
core   +1 more source

The T102C Polymorphism of the 5-HT2A-Receptor Gene in Fibromyalgia

open access: yesNeurobiology of Disease, 1999
Based on a possible involvement of serotonergic dysfunction in the pathophysiology of fibromyalgia (FM) and on preliminary reports of a possible genetically driven vulnerability for this disorder we investigated the silent T102C polymorphism of the 5-HT2A-receptor gene in 168 FM patients and 115 healthy controls.
Brigitta Bondy   +11 more
openaire   +3 more sources

Enhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143-deficient mice

open access: yesJournal of Pharmacological Sciences
Hallucinogens, such as lysergic acid diethylamide, act primarily through the 5-hydroxytryptamine 2A (5-HT2A) receptor, but their regulatory mechanisms remain unclear.
Daiki Masukawa   +5 more
doaj   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou   +3 more
wiley   +1 more source

Biophysical Validation of Serotonin 5-HT2A and 5-HT2C Receptor Interaction

open access: yes, 2018
Data supporting "Biophysical Validation of Serotonin 5-HT2A and 5-HT2C Receptor ...
daniel felsing (5688335)
core   +1 more source

A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction [PDF]

open access: yes, 2003
The serotonin (5-hydroxytryptamine) 2A receptor (5-HT2A) is an important G protein-coupled receptor (GPCR) that mediates the effects of hallucinogens and is the target of a number of commonly prescribed medications including atypical antipsychotics ...
Xia, Zongqi   +11 more
core   +1 more source

Image3_The serotonin receptor 5-HT2A modulates lifespan and protein feeding in Drosophila melanogaster.pdf

open access: yes, 2022
The conserved neurotransmitter serotonin has been shown to be an important modulator of lifespan in specific nutritional contexts; however, it remained unclear how serotonin signaling influences lifespan under normal conditions.
Saige S. Porter (14200154)   +4 more
core   +1 more source

An ETH‐LAD trip with unfavourable consequences: A case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH‐LAD (6‐ethyl‐6‐nor‐lysergic acid diethylamide), the N‐ethyl derivative of LSD.
Johannes Nadler   +6 more
wiley   +1 more source

Image1_The serotonin receptor 5-HT2A modulates lifespan and protein feeding in Drosophila melanogaster.pdf

open access: yes, 2022
The conserved neurotransmitter serotonin has been shown to be an important modulator of lifespan in specific nutritional contexts; however, it remained unclear how serotonin signaling influences lifespan under normal conditions.
Saige S. Porter (14200154)   +4 more
core   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy